Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases of abnormal mineralization, announced that co-founder and CEO Axel Bolte will present at two upcoming virtual investor conferences. The 2021 Jefferies London Virtual Healthcare Conference will feature an on-demand presentation starting November 18, 2021, at 3:00 a.m. ET, while the Piper Sandler 33rd Annual Virtual Healthcare Conference will host a fireside chat available on-demand from November 22, 2021, at 10:00 a.m. ET. Presentations will be accessible for 60 days on the company’s website.
- None.
- None.
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following virtual investor conferences:
- The 2021 Jefferies London Virtual Healthcare Conference. The presentation will be available on-demand beginning at 3:00 a.m. ET/8:00 a.m. GMT on Thursday, November 18, 2021.
- The Piper Sandler 33rd Annual Virtual Healthcare Conference. The fireside chat will be available on-demand beginning at 10:00 a.m. ET on Monday, November 22, 2021.
A replay of the pre-recorded presentations can be accessed from the Investor & News section of Inozyme’s website under events and will be available for up to 60 days following the events.
About Inozyme Pharma
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.
Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
stefan.riley@inozyme.com
Media:
SmithSolve
Matt Pera
973-886-9150
matt.pera@smithsolve.com
FAQ
What conferences will Inozyme Pharma's CEO participate in?
When can I access the presentations from Inozyme Pharma's conferences?
What is Inozyme Pharma focusing on in their research?
What is the ticker symbol for Inozyme Pharma?
